Sofinnova Telethon Fund backs Naldini's gene therapy biotech; ORIC prices $75M IPO
→ The Sofinnova Telethon Fund has found a new gene therapy upstart to back. The fund selected Genespire for its portfolio, tapping a biotech inspired …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.